Are we as good as we think we are?

Quote
anonymous said:
So I just heard that the fill & finish plant for dupilumab has been moved. So to correct my previous post, sounds like they have controlled everything they can control with the launch and are waiting on FDA.
Click to expand...

Yes, you're correct. The truth is, this new place is even more fucked up with multiple 483's to clear up.
 






anonymous said:
dear senior management, this has been a great gig, thank you from one of your eylea reps. Please remember that we have had to pay royalties to Genentech for patent issues re eylea, lost a drug recently in ph 3, will likely have to pay Amgen for patent infringement on pcsk9, are in a clinical hold with the lower back pain drug and now this with sarilumab. Yes, I know that had nothing to do with us and will likely be resolved soon but we are not as great as we think we are. The commercial team works very hard to fund this pipeline and the drug does not sell itself. I know our colleagues in the other therapeutic areas are working hard to be successful but please knock off the holier than thou shit coming from the top. Btw...I hope science magazine didn't get our ranking wrong but let's be realistic we have lots of issues to address and jacking up eylea goals to cover our errors only makes the eylea team resent the company we were so excited to join.
Click to expand...

Regeneron has some great employees. It's a shame we know how to get the job done but are directed by people don't know what they're doing. Whatever you do, don't step out of the box or you'll get burned. Get out as soon as you can!
 


















Top Bottom
Back
Quote